He Guodong, Huang Jingnan, Zeng Zhaodi, Sun Huiyu, Wu Chao, Xu Qi, Hu Chuanchen, Jin Bei, Tong Minfeng, Wang Chengde
Department of Neurosurgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang, China.
Department of Neurosurgery, Wencheng Hospital Affiliated of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Front Cell Dev Biol. 2025 Aug 14;13:1650885. doi: 10.3389/fcell.2025.1650885. eCollection 2025.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder primarily characterized by memory impairment and cognitive decline, for which no curative treatment is currently available. Existing therapeutic strategies, such as cholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists, can only provide limited symptomatic relief and fail to halt disease progression. In recent years, stem cell therapy has emerged as a promising approach for AD due to its multifaceted mechanisms of action. The therapeutic effects of stem cells in AD are mainly attributed to their ability to differentiate into functional neurons or glial cells, thereby replacing damaged cells and repairing neural networks. In addition, stem cells secrete neurotrophic and anti-inflammatory factors that contribute to the improvement of the brain microenvironment. Furthermore, they can regulate neuroinflammation, promote the clearance of β-amyloid (Aβ) deposits, and suppress neuroinflammation, thus potentially slowing disease progression. However, several challenges remain, including low cell survival rates, immune rejection, tumorigenic risks, and difficulties in crossing the blood-brain barrier. Looking ahead, the integration of advanced technologies such as organoid models, gene editing, artificial intelligence, and multi-omics approaches may drive substantial progress in the clinical translation of stem cell therapies for AD. Although still in its early stages, the future of this therapeutic strategy holds great promise.
阿尔茨海默病(AD)是一种进行性神经退行性疾病,主要特征为记忆障碍和认知衰退,目前尚无治愈性治疗方法。现有的治疗策略,如胆碱酯酶抑制剂和N-甲基-D-天冬氨酸(NMDA)受体拮抗剂,只能提供有限的症状缓解,无法阻止疾病进展。近年来,干细胞疗法因其多方面的作用机制而成为治疗AD的一种有前景的方法。干细胞在AD中的治疗作用主要归因于其分化为功能性神经元或神经胶质细胞的能力,从而替代受损细胞并修复神经网络。此外,干细胞分泌神经营养和抗炎因子,有助于改善脑微环境。此外,它们可以调节神经炎症,促进β-淀粉样蛋白(Aβ)沉积的清除,并抑制神经炎症,从而有可能减缓疾病进展。然而,仍存在一些挑战,包括细胞存活率低、免疫排斥、致瘤风险以及穿越血脑屏障的困难。展望未来,类器官模型、基因编辑、人工智能和多组学方法等先进技术的整合可能会推动干细胞疗法治疗AD临床转化取得重大进展。尽管仍处于早期阶段,但这种治疗策略的未来前景广阔。